Tom Burt

Tom joined the Sofinnova Crossover Fund team in June 2017 from Peel Hunt, where he was a senior research analyst for healthcare & life sciences.

He has 11 years of diverse investing expertise, with over $1.5 billion in total completed transactions. Tom, with an EngD in biochemical engineering and experience working on the manufacture of vaccines at GlaxoSmithKline, brings an engineer’s mindset to the world of venture capital. Tom worked for several years with Jacques Theurillat at Ares Life Sciences. Prior to that, he was at Novo Growth Equity, a Danish fund focused on late-stage investments in both public and private life science companies, and a member of Piper Jaffray’s European healthcare investment banking team. He holds Doctorate and Master’s degrees in biochemical engineering (University College London and the University of Birmingham) and an undergraduate degree in Biotechnology. Tom is a chartered member of the Association of Engineering Doctorates.